NanoViricides, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $4.7M | $5.5M | $5.4M | $6.4M |
| SG&A Expense | $3.6M | $4.0M | $3.1M | $2.6M |
| Operating Income | $-8.3M | $-9.6M | $-8.5M | $-8.9M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | $49.8K | $938 |
| Pretax Income | $-8.2M | — | — | — |
| Income Tax Expense | — | — | — | — |
| Net Income | $-8.2M | $-9.5M | $-8.3M | $-8.6M |
| Net Margin | — | — | — | — |
| EPS (Basic) | $-0.41 | $-0.63 | $-0.70 | $-0.74 |
| EPS (Diluted) | $-0.41 | $-0.63 | $-0.70 | $-0.74 |
| Shares Outstanding (Basic) | 20.2M | 15.1M | 11.9M | 11.6M |
| Shares Outstanding (Diluted) | 20.2M | 15.1M | 11.9M | 11.6M |
| Dividends Per Share | — | — | — | — |